Having elevated blood eosinophil counts (BEC) along with three other clinical characteristics help identify a subgroup of patients with COPD* who are most likely to benefit from benralizumab in terms of exacerbation reduction, according to a prespecified pooled analysis of the phase III GALATHEA and TERRANOVA** trials.
Exposure to air pollution increases the risk of death in infants and impairs lung function in young children, according to two studies presented at the recently concluded International Congress of the European Respiratory Society (ERS 2019).
The use of low-dose indacaterol acetate/mometasone furoate (IND/MF), a long-acting β2-agonist/inhaled corticosteroid (LABA/ICS) combination, significantly improves trough FEV1* in symptomatic patients with poorly controlled asthma, according to the QUARTZ** study presented at ERS 2019.
The use of single-inhaler triple therapy yields meaningful improvements across a range of chronic obstructive pulmonary disease (COPD) endpoints over time compared with dual therapies, according to data from the IMPACT* trial presented at the 2019 European Respiratory Society (ERS) International Congress.
Adding a LAMA* to the double combination therapy of ICS** plus LABA*** in a single inhaler improves lung function and reduces exacerbations in patients whose asthma is inadequately controlled with the combination treatment, according to the TRIMARAN and TRIGGER# studies presented at ERS 2019.
Maintenance therapy with the common macrolide antibiotic azithromycin halves the rate of respiratory events in patients with primary ciliary dyskinesia (PCD) – otherwise known as immotile-cilia syndrome – in the first multicentre randomized controlled clinical trial of azithromycin in PCD.
Babies born to mothers exposed to high levels of bisphenol A during pregnancy are at a greater risk of wheezing and poor lung function, according to a new study presented at the recently concluded International Congress of the European Respiratory Society (ERS 2019).
Transbronchial lung cryobiopsy performs well in diagnosing interstitial lung disease, showing an accuracy similar to that of surgical lung biopsy, according to the results of the COLDICE study presented at the European Respiratory Society (ERS) International Congress 2019.
Dupilumab significantly improves all disease components of severe, uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP) — a primarily type 2 inflammatory condition — compared with placebo when both are added to standard of care. Furthermore, the treatment benefit extends to even patients with comorbid nonsteroidal anti-inflammatory drug-exacerbated respiratory disease (NSAID-ERD), according to a pooled analysis of the LIBERTY NP SINUS-24 and -52* trials presented at ERS 2019.
The tyrosine kinase inhibitor nintedanib significantly delayed progression of a wide range of fibrosing interstitial lung diseases (ILDs) other than idiopathic pulmonary fibrosis (IPF) compared with placebo, according to the INBUILD* study presented at ERS 2019.
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.